Emicizumab for hemophilia A without inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emicizumab for hemophilia A without inhibitors

Published:2019-06-04 Issue:7 Volume:12 Page:515-524
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Cafuir Lorraine¹,Kruse-Jarres Rebecca²,Mancuso Maria Elisa³^ORCID,Kempton Christine L¹

Affiliation:

1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

2. Division of Hematology, University of Washington, Seattle, Washington, USA

3. Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

Funder

not funded

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2019.1624519

Reference48 articles.

1. The History of Hemophilia

2. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens

3. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

4. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

5. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dental management of people with complex or rare inherited bleeding disorders;Haemophilia;2024-04

2. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

3. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis;Sao Paulo Medical Journal;2024

4. Maladaptive lymphangiogenesis is associated with synovial iron accumulation and delayed clearance in factor VIII–deficient mice after induced hemarthrosis;Journal of Thrombosis and Haemostasis;2023-09

5. Considerations for shared decision management in previously untreated patients with hemophilia A or B;Therapeutic Advances in Hematology;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3